Background and objectives: Little is known about the consequences of chronic
0.64; P = 0.001), and forced vital capacity (r = 0.56, 95%CI = 0.34, 0.72; P < 0.001). In multivariable analysis, SPD remained associated only with VO 2 max.
Conclusion:
Patients with chronic sarcoidosis appear to have reduced DL PA mainly because of compromised VO 2 max.
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| INTRODUCTION
Sarcoidosis is a systemic disease of unknown cause that can affect many organs but that most frequently (90%-95% of cases) affects the lungs. 1 Together, sarcoidosis and idiopathic pulmonary fibrosis represent the two most common etiologies of interstitial lung disease. 1 Histologically, sarcoidosis is characterized by the formation of epithelioid and giant cell granulomas without caseous necrosis, 2 and it is usually classified in five stages based on radiological findings.
Stage IV corresponds to the chronic fibrosing form of the disease, which accounts for approximately 5.4% of pulmonary sarcoidosis cases. 3 Patients with chronic respiratory diseases often display disabling dyspnea associated with a progressive reduction in daily life physical activity (DL PA ), as has previously been demonstrated in patients with interstitial lung diseases, including idiopathic pulmonary fibrosis. 4 Reduced physical activity is an important clinical parameter related to increased morbidity, mortality, and hospitalizations in many chronic diseases. 5 Little is known about DL PA in patients with chronic sarcoidosis. [6] [7] [8] [9] Saligan showed a reduction in physical activity associated with fatigue, depressive symptoms, and a shorter distance in the 6-minute walk test (6MWT), 9 whereas Bahmer et al found a significant association with 6MWT distance and quality of life scores but only a weak association with fatigue. 6 However, these studies examined patients with a variety of respiratory conditions, and relatively few of them had chronic fibrotic disease.
With this in mind, we sought to quantify DL PA in patients with stage IV chronic sarcoidosis and determine the relationships between two-defined DL PA parameters and a number of pulmonary function, aerobic capacity, and quality of life measures. The main objective of this work was to evaluate DL PA in patients with chronic stage IV sarcoidosis compared with healthy control subjects. The secondary objective was to determine the factors associated with DL PA in patients with chronic sarcoidosis.
| METHODS

| Patients
Fifty-three patients with stage IV chronic sarcoidosis 10 were enrolled in the study. Of these, 29 were part of the National PHRC 2012- 
| Assessment of daily life physical activity
Subjects were equipped with a physical activity monitor (SenseWear Pro armband and SenseWear software version 8.0; BodyMedia Inc., Pittsburgh, Pennsylvania, United States) and instructed to wear the device continuously, except while showering or bathing, for five consecutive days (three weekdays and two weekend days). The device was positioned on the upper right arm at the midpoint between the acromion and the olecranon, as previously described. 11 DL PA was assessed by measuring the number of steps per day (SPD) and the total daily energy expenditure (TEE, in kcal/day). All functional tests and questionnaires were performed on the same day, prior to the 5-day DL PA monitoring. 
| Pulmonary function tests
| Six-minute walk test (6MWT)
The 6MWT was performed in accordance with international recom- 
| Fatigue
Fatigue occurring during the patients' daily lives was assessed using the Fatigue Assessment Scale (FAS) questionnaire, in which a score greater than 22 (on a scale of 10-50) is considered clinically significant. 19 
| Quality of life
The patients indicated their overall quality of life using the Visual Simplified Respiratory Questionnaire (VSRQ). A score of at least 80 (on a scale of 0-100) indicates a satisfactory quality of life. 
| Anxiety and depression
The Hospital Anxiety and Depression Scale (HADS) was designed to identify and quantify the two most common forms of psychological disorders in medical patients. 21 For both subscales, a score of 8 to 10 (on a scale of 0-21) is indicative of uncertain symptoms, and a score greater than 11 is indicative of clinically relevant symptoms. 
| Statistical analysis
| RESULTS
The characteristics of the patients with sarcoidosis and healthy control subjects are summarized in Tables 1 and Table 2 . Pulmonary function tests showed that DLco was reduced (<80% predicted) in 46 of the 53 (87%) patients with sarcoidosis. A restrictive pattern (TLC < 80% predicted) was observed in 20 patients (38%), and an obstructive pattern (FEV 1 /FVC < 70%) was seen in 31 patients (58%). Twenty-two patients (41%) displayed significant fatigue (FAS score > 22), 14
(26%) had a significant HADS anxiety score (≥11), and 11 (20%) had of these, 45.3% were also taking additional immunosuppressive drugs.
The DL PA parameters for patients with sarcoidosis and control subjects are shown in Table 3 
were significantly lower in patients than in controls (Supplementary   table 1) . Since the difference in TEE was considered not to be clinically significant, the multivariable analysis were not performed. and SF-12 questionnaires). 6 However, it is important to note that Bahmer et al included only three patients with chronic sarcoidosis stage IV in their study cohort, which could explain the differences between their and our results. Indeed, the mean (±SD) SPD recorded in that study (7490 ± 3007) 6 was higher than in our study (6395 ± 4119).
| DISCUSSION
Our data suggest that submaximal stress tests are insufficient to evaluate the mechanisms underlying the reduced DL PA in patients with sarcoidosis. To our knowledge, only one study has previously evaluated parameters other than SPD to quantify DL PA in patients with chronic sarcoidosis. 7 Although daily energy expenditure was also associated with VO 2 max in that study, only patients with less severe disease (stage II) were evaluated. 7 We also found that total daily expenditure was correlated with FEV 1 . Bahmer et al 6 found that FEV 1 was associated with the 6MWT distance but not with SPD in patients with sarcoidosis. However, the mean FEV 1 in that study was less severe than in our study. Similar findings to ours have been reported in patients with chronic obstructive pulmonary disease, who display a progressive decrease in FEV 1 that is paralleled by a decrease in physical activity. 23 Our study is the first to show that the obstructive ventilatory defect is correlated with DL PA in patients with sarcoidosis and might explain part of the reduction in daily TEE.
Interestingly, both the pulmonary function pattern and the high percentage of patients with an obstructive ventilatory defect in our cohort are similar to those reported by Nardi et al, who examined a large group of patients with stage IV sarcoidosis. 24 Although patients with sarcoidosis commonly show fatigue 25 associated with both a poor quality of life 26 and a shorter 6MWT FIGURE 1 Physical activity in daily life for patients with sarcoidosis and healthy controls (A) Number of steps per day and (B) total daily energy expenditure in healthy controls (n = 28) and patients with chronic sarcoidosis (n = 53). Lines indicate mean. Differences were analyzed using student's t test. Only a fraction of the reduction in DL PA in patients with sarcoidosis could be explained by the resting and exercise functional parameters examined here, suggesting that it may be important to investigate the influence of environmental and sociodemographic factors in future studies. In support of this, a study of patients with chronic obstructive pulmonary disease found that dog ownership or having small children was significantly associated with time spent in moderate to sustained physical activities (3-6 metabolic equivalents). 29 Place of residence and psychological factors also seem to be important influences on the level of physical activity. Sallis et al found an association between daily physical activity in healthy adults, as measured by an accelerometer and the density of neighborhood parks and public transport. 30 However, there have been no comparable studies in patients with respiratory diseases. Bauman et al reviewed 16 articles on healthy adults with a history of physical activity during adolescence and adulthood, and they found that self-efficacy (confidence in the ability to be active in specific situations) is the most important determinant of physical activity. 31 These different sociodemographic elements must be studied in various patient populations to determine their relevance to each specific respiratory disease and their contributions to interindividual variability in DL PA .
In addition to the limitations inherent to the observational exploratory design, our study has several weaknesses. There was no formal sample size calculation, so we cannot exclude the possibility that differences may have been overlooked because of inadequate statistical power. In a posterior power calculation, the smallest significant difference that our sample size (53 patients with sarcoidosis and 28 healthy controls) allowed us to detect with 80% power was 0.7 (standardized mean difference), which is interpreted as a large effect size. 32 The lack of a validation dataset was also a limitation. Additionally, we also cannot exclude response bias in the questionnaires.
| CONCLUSION
DL PA is reduced in patients with chronic stage IV sarcoidosis compared with control subjects. Our findings implicate VO 2 max, which explains 13.3% of SPD, as significant influence on DL PA in these patients. However, pulmonary function tests were insufficient to evaluate DL PA in our study, and other parameters must be evaluated to understand all determinants of DL PA in patients with chronic sarcoidosis. Future studies should also evaluate how DL PA changes during and after pulmonary rehabilitation. All variables associated with number of steps per day in the univariable analyses (at P < 0.10) were considered as candidate variables for multivariable analysis. The multivariable analysis was conducted using a forwardstepwise selection approach, as specified in the statistical analysis section, by including pre-specified confounders as forced variables (age, BMI, and sex).
